Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | BCL2 | P10415 | 2/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409791 | 1.00 | CTSS (0.60) | CTSSCTSKHDAC8BCL2MCL1 | |
| SCHEMBL6803437 | 0.95 | HDAC8 (0.64) | CTSSCTSKHDAC8BCL2MCL1 | |
| SCHEMBL6803446 | 0.95 | HDAC8 (0.64) | CTSSCTSKHDAC8BCL2MCL1 | |
| SCHEMBL3008259 | 0.95 | HDAC8 (0.59) | CTSSCTSKHDAC8CTSBCTSL | |
| SCHEMBL3008254 | 0.95 | HDAC8 (0.59) | CTSSCTSKHDAC8CTSBCTSL | |
| SCHEMBL27744372 | 0.91 | CYP17A1 (0.53) | CTSSCTSKHDAC8BCL2MCL1 | |
| SCHEMBL18444304 | 0.90 | PPARG (0.57) | CTSSCTSKHDAC8BCL2MCL1 | |
| SCHEMBL28586432 | 0.90 | PPARG (0.57) | CTSSCTSKHDAC8BCL2MCL1 | |
| SCHEMBL18444303 | 0.90 | PPARG (0.57) | CTSSCTSKHDAC8BCL2MCL1 | |
| SCHEMBL18474966 | 0.88 | PPARG (0.55) | CTSSCTSKHDAC8CTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753733-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | Avanir Pharmaceuticals (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123700-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | AVANIR PHARMACEUTICALS | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | LDLR, NPC1L1, CETP | CTSS 2187/4885CTSK 1834/4885HDAC8 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.